Key facts
- This page summarizes David Arkowitz's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 Oct 2022, 18:05.
David Arkowitz - 15 Jun 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- MCRB
- Reported as of
- 15 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Oct 2022, 18:05:58 UTC
- Prior SEC filing
- 08 Feb 2022
- Next SEC filing
- 22 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Arkowitz filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 31 Oct 2022.
Change
- Previous filing in this sequence was filed on 08 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MCRB
transaction
Common stock
Options Exercise
- Transaction value
- $0
- Shares
- +5,000
- Change %
- +7.6%
- Price
- $0.000000
- Shares after
- 70,492
- Date
- 15 Jun 2022
- Ownership
- Direct
MCRB
transaction
Common stock
Award
- Transaction value
- $0
- Shares
- +42,500
- Change %
- +60%
- Price
- $0.000000
- Shares after
- 112,992
- Date
- 27 Oct 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MCRB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 42,500 shares.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Footnote F3
On June 1, 2021, the reporting person was granted an award of restricted stock units, 100% of which vested and settled on June 15, 2022.